Corcept Therapeutics (CORT) Competitors

Corcept Therapeutics (NASDAQ:CORT) and Annovis Bio (NYSE:ANVS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Does the media refer more to CORT or ANVS?

In the previous week, Corcept Therapeutics had 19 more articles in the media than Annovis Bio. MarketBeat recorded 25 mentions for Corcept Therapeutics and 6 mentions for Annovis Bio. Corcept Therapeutics' average media sentiment score of 1.08 beat Annovis Bio's score of 0.86 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	15 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annovis Bio	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is CORT or ANVS more profitable?

Corcept Therapeutics has a net margin of 18.51% compared to Annovis Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 20.10% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	18.51%	20.10%	16.20%
Annovis Bio	N/A	-206.01%	-158.26%

Do analysts prefer CORT or ANVS?

Corcept Therapeutics currently has a consensus target price of $134.50, suggesting a potential upside of 87.46%. Annovis Bio has a consensus target price of $18.00, suggesting a potential upside of 559.34%. Given Annovis Bio's higher probable upside, analysts clearly believe Annovis Bio is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Annovis Bio	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Do institutionals and insiders hold more shares of CORT or ANVS?

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 20.8% of Corcept Therapeutics shares are held by insiders. Comparatively, 20.8% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Which has more risk and volatility, CORT or ANVS?

Corcept Therapeutics has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.

Which has preferable earnings & valuation, CORT or ANVS?

Corcept Therapeutics has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$675.04M	11.20	$141.21M	$1.13	63.50
Annovis Bio	N/A	N/A	-$24.59M	-$2.04	-1.34

Summary

Corcept Therapeutics beats Annovis Bio on 12 of the 14 factors compared between the two stocks.